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Table 1. Baseline and 3 month Data
Group1(n¼16) Group2(n¼17) Group3(n¼14)
baseline After3month baseline After3month baseline After3month
Hb(g/dl 8.9þ1.4 8.8þ1.3 8.8þ1.3 9.5þ1.2 9.0þ1.2 9.6þ1.2
Fe(u/L) 55.84þ23 58.6þ19 58.57þ25 63.7þ22 61.12þ21 6729þ19
EPOdose(unit/week)14729 14538 15584 12369 14986 11345
Ferritin(ug/l) 764þ217 781þ192 783þ191 646þ189 754þ220 634þ231
Transferrin
saturation(%)
18þ6.4 18þ5.8 20.6þ5.5 26.4þ4.4 19.8þ4.9 24.5þ3.2
*is po0.5
Abstracts: The 16th International Congress on Nutrition and Metabolism in Renal Disease 2012 A39ferric citrate experienced signiﬁcant increases in serum ferritin (þ10%) and
TSAT (þ18%) after 4 weeks of treatment.
We analyzed electronic medical records of patients with concurrent rises
in TSAT (Z 10%) and ferritin (15% to 25%) between 6/1/08 and 12/31/10,
excluding patients with signiﬁcant change in iron or erythropoiesis-
stimulating agent (ESA) dose, hemoglobin, or change in PB during the prior
month. We assessed changes in epoetin alfa and iron dosing when
physicians observed these increases in lab values. We constructed a cost
offset model from a per patient per month (PPPM) considering average
sales price of epoetin and iron that assumed equivalent phosphorus
outcomes and pricing across all PB.
The analysis included 2,037 concurrent, non-treatment related rises in
ferritin and TSAT. Decreases in dose/dialysis session in mean epoetin and
iron use 2 months following the index date represented an average
combined savings of $90.51 to $181.01 PPPM. The model was most
sensitive to baseline drug doses: patients at highest baseline epoetin doses
(4 9,000U/session) showed savings of $471.80 to $943.61 PPPM.
Based on actual physician behavior in response to ferritin and TSAT
increases and ferric citrate clinical trial results, and assuming equivalent
pricing to other PBs, there would be cost savings with ferric citrate use
through reduced ESA and iron use.
http://dx.doi.org/10.1016/j.krcp.2012.04.41491
EFFECT OF ASCORBIC ACID ON EPO-HYPORESPONSIVE ANEMIA IN
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We performed the present study to evaluate the efﬁcacy of intravenous
and oral ascorbic acid in improving anemia and iron availability on EPO-
hyporesponsive anemia in hemodialysis patients with hyperferritinemia.
This study of three months duration was conducted in 49 patients with Hb
o11 g/dL and ferritin levels greater than 300 ng/ml. Blood samples for
measurement of Hb, Hct, serum iron, ferritin, TIBC, transferrin saturation,
EPO dose were obtained after baseline and at the end of study after three
months. Patients were randomly divided into three groups. 16 patients had
received standard care(group 1), 17 patients had received standard care
and daily oral ascorbic acid at a dose of 500 mg/day(group 2), and 16
patients had received standard care and 300mg of intravenous vitamin C
with each dialysis session(group 3). Forty-seven patients completed the
study. All of patients dialyzed 4 hours, 3 times a week with similar kt/V.
Hb, serum iron, serum ferritin, transferrin saturation and EPO dose was
similar in the three groups at baseline. After 3 month, Hemoglobin and
hematocrit and transferrin saturation signiﬁcantly increased in group 2,3.
but not changed in group 1. EPO dose and ferritin level decreased in group
2,3. but not changed in group 1. There was no difference between group
2 and 3. In conclusion, intravenous or oral ascorbic acid therapy can
improve hyperferritinemia and EPO hyporesponsive anemia in
hemodialysis patients. And The effect of intravenous and oral ascorbic acid
are similar.
http://dx.doi.org/10.1016/j.krcp.2012.04.41592
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The aim of the study was to analyse the impact of renal transplantation
on body composition (Body Cell Mass) in adult kidney transplant
recipients.Body Cell Mass (BCM) was calculated from total body potassium
(TBK), determined from K-40 in a whole body counter. Patients were
measured before transplantation and 3 months, 1 year and 2 years after
transplantation. Patients were encouraged to take part in physical exercise,
but supervised physical training was not included in the study Out of 50
included patients, 44 have had a kidney transplant (9 F, 35 M). Mean age at
transplantation was 49 (23-72) years. Before transplantation, mean BW
was 80 (SD 13) kg and mean BMI 25,6 (SD 4) kg/m2. Mean TBK was 3162
(SD 690) mmol, corresponding to 90 % of predicted value. In the 1 year
follow up, no signiﬁcant changes in TBK (n¼42) were found, nor in patients
examined 2-3 years after transplantation (n¼35). To examine whether
post transplantation improvement of BCM will appear later, as has been
seen in Liver Transplant recipients, patients were invited to a follow up
measurement. So far, 11 patients have repeated the measurement 6 (4½-
7½) years after transplantation. TBK improvements of 410% were seen in
4 patients, decreases of 410% in 2 patients, and changes of a lower
magnitude in remaining patients. In conclusion, no increase in Body Cell
Mass was seen in this unselected group of kidney transplant recipients
during the ﬁrst 2-3 years after transplantation. Pro catabolic events and
low physical activity may explain this lack oﬁmprovement.
http://dx.doi.org/10.1016/j.krcp.2012.04.41693
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OVERALL POPULATION AND SPECIFIC SUBPOPULATIONS
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Whether excess sodium intake is a risk factor for coronary heart disease
(CHD) has recently been challenged, despite compelling evidence for its
adverse effects on blood pressure and extracellular volume. We examined
the association between sodium intake and risk of CHD in the overall
population and in subgroups potentially more susceptible to the
detrimental effects of high sodium intake.
We included 7779 adults without previous cardiovascular diseases or
cancer at baseline (1997-1998) from the observational, community-based
PREVEND study. Sodium intake was estimated from two 24-h urine
collections and normalized to creatinine excretion. Hypertension and
N-Terminal pro-B-type Natriuretic Peptide (NTproBNP) levels above the
sex-speciﬁc median were deﬁned as predisposing factors to the adverse
effects of high sodium intake. We documented 464 events, during a median
follow-up of 10.5 y, There was some evidence for a trend between sodium
intake and risk of CHD in the entire cohort after adjustment for CHD risk
factors [Hazard ratio (HR), 1.06; 95% conﬁdence interval (CI), 0.97-1.17 per
SD increment]. Each SD increment in sodium intake was associated with a
higher risk for CHD only among subjects with hypertension (n¼2453; HR,
1.14; 95% CI, 1.01-1.29) and with elevated NTproBNP levels (n¼3796; HR,
1.14; 95% CI, 1.02-1.28).
In conclusion, a higher sodium intake was associated with an increased
risk of CHD among subjects with hypertension and elevated levels of
